GlassScriptPhysician profile
Charles M O Connor
NPI 1720053523
$1,221.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $180 · 2021: $389.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $375.59 | 2019-2021 | |
| Abbvie INC. | $243.19 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.09 | 2019-2021 | |
| Pfizer INC. | $138.00 | 2019-2021 | |
| Janssen Biotech, INC. | $104.62 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $37.38 | 2019 | |
| Daiichi Sankyo INC. | $33.27 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $31.16 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $27.12 | 2021 | |
| Merck Sharp & Dohme LLC | $26.94 | 2021 | |
| Ucb, INC. | $26.92 | 2019 | |
| Redhill Biopharma INC. | $14.09 | 2021 | |
| Gilead Sciences, INC. | $14.04 | 2021 | |
| Romark Laboratories, Lc | $5.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles O Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.